A metabolomic study on the anti-depressive effects of two active components from Chrysanthemum morifolium
Source abstract
Abstract
Chrysanthemum morifolium (Chr) is a traditional Chinese medicine (TCM) that has been used in the treatment of inflammation-linked diseases for hundreds of years. Naringenin (Nar) and apigenin (Api) are the major active components in aqueous extracts of C. morifolium. The aim of our study was to clarify the roles of Chr, Nar and Api in ameliorating depression-like behaviour induced by corticosterone. First, the behavioural and biochemical indicators closely related to depression were examined to evaluate the therapeutic effects of Chr/Nar/Api on a depression model. Then, a metabolomics approach was utilized to screen for biomarkers and related pathways between a control group and Chr/Nar/Api groups. The comprehensive results revealed that Chr/Nar/Api exerted anti-depressant effects through interfering with tryptophan metabolism, arginine and prolinemetabolism, citrate cycle, niacin and niacinamide metabolism, phenylalanine metabolism, and alanine, aspartate and glutamate metabolism. The mechanism of Chr/Api/Nar in the treatment of depression was elucidated based on material and energy metabolism. Moreover, Nar could be used as a substitute for Chr for reversing depression-like behaviour, and Api was similar to a positive drug in terms of function on depression. The integrated metabolomics approach demonstrated here should be an effective method for interpreting the function of herbs from TCM and clarifying the mechanism of their components in future studies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Tryptophan and brain disorders · Metabolomics and Mass Spectrometry Studies · Stress Responses and Cortisol
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Pharmacy, Henan University of Chinese Medicine
Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment and Chinese Medicine Development of Henan Province
Funding
The Major Science and Technology Projects · National Key Research and Development Project · ZhongYuan One Thousand People Plan”-Zhongyuan Leading Talent · National Natural Science Foundation of China
References (46)
Show source-provided references
1. 10.1016/S0140-6736(18)31948-210.1016/S0140-6736(18)31948-2 ↗
2. 10.1186/s12888-016-1173-210.1186/s12888-016-1173-2 ↗
3. 10.1016/S0140-6736(17)32802-710.1016/S0140-6736(17)32802-7 ↗
4. 10.1016/j.jad.2016.12.04810.1016/j.jad.2016.12.048 ↗
5. 10.1016/j.jad.2017.11.06310.1016/j.jad.2017.11.063 ↗
6. 10.1021/jf010164e10.1021/jf010164e ↗
7. 10.4103/1673-5374.17773510.4103/1673-5374.177735 ↗
8. 10.3390/brainsci911029610.3390/brainsci9110296 ↗
9. 10.1016/j.bbi.2019.10.01710.1016/j.bbi.2019.10.017 ↗
10. 10.1111/1440-1681.1288010.1111/1440-1681.12880 ↗
11. Wojnar W, Zych M, Kaczmarczyk-Sedlak I. Antioxidative effect of flavonoid naringenin in the lenses of type 1 diabetic rats. Biomed Pharmacother. 2014;307:1024–1031.
12. 10.1002/jsfa.395910.1002/jsfa.3959 ↗
13. 10.1016/j.lfs.2016.07.00710.1016/j.lfs.2016.07.007 ↗
14. 10.1016/j.biopha.2018.04.11010.1016/j.biopha.2018.04.110 ↗
15. 10.1016/j.taap.2018.07.01010.1016/j.taap.2018.07.010 ↗
16. 10.1007/s11064-016-1949-210.1007/s11064-016-1949-2 ↗
17. 10.1016/j.bbr.2015.09.03110.1016/j.bbr.2015.09.031 ↗
18. 10.1038/4551054a10.1038/4551054a ↗
19. 10.1038/nrd72810.1038/nrd728 ↗
20. 10.1039/B811850G10.1039/B811850G ↗
21. 10.1016/j.ecoenv.2018.07.08010.1016/j.ecoenv.2018.07.080 ↗
22. 10.1111/jne.1203410.1111/jne.12034 ↗
23. 10.1177/107385840426738210.1177/1073858404267382 ↗
24. 10.1111/j.1742-4658.2012.08551.x10.1111/j.1742-4658.2012.08551.x ↗
25. 10.1016/j.jpsychires.2019.10.00410.1016/j.jpsychires.2019.10.004 ↗
26. 10.3389/fnins.2019.0036410.3389/fnins.2019.00364 ↗
27. Fei L, Xiao-Chun Z, Qing-Mo L. 1-methylhydantoin inhibits secretion of growth hormone in rabbits. Chin Pharmacol Bull. 2017;33:401–406.
28. 10.1038/nm.316210.1038/nm.3162 ↗
29. 10.1093/cvr/cvy05410.1093/cvr/cvy054 ↗
30. 10.1016/j.pnpbp.2018.05.00110.1016/j.pnpbp.2018.05.001 ↗
31. 10.1016/j.psychres.2003.12.02510.1016/j.psychres.2003.12.025 ↗
32. 10.2165/00007256-200737120-0000510.2165/00007256-200737120-00005 ↗
33. 10.1046/j.1365-201X.1998.0298f.x10.1046/j.1365-201X.1998.0298f.x ↗
34. 10.1007/s11064-019-02758-910.1007/s11064-019-02758-9 ↗
35. 10.4088/JCP.14r0917910.4088/JCP.14r09179 ↗
36. 10.1007/978-1-4939-7595-2_510.1007/978-1-4939-7595-2_5 ↗
37. 10.1074/jbc.275.19.1406410.1074/jbc.275.19.14064 ↗
38. 10.1177/117864691877665810.1177/1178646918776658 ↗
39. 10.3390/ijms2004097410.3390/ijms20040974 ↗
40. Weiss N, Mochel F, Rudler M, et al. Peak hyperammonemia and atypical acute liver failure: the eruption of an urea cycle disorder during hyperemesis gravidarum. J Hepatol. 2017; 68: 185–192.
41. 10.1152/ajpgi.00244.201410.1152/ajpgi.00244.2014 ↗
42. 10.1124/dmd.32.1.1010.1124/dmd.32.1.10 ↗
43. 10.1021/pr201008210.1021/pr2010082 ↗
44. 10.1016/j.pneurobio.2015.12.00110.1016/j.pneurobio.2015.12.001 ↗
45. 10.1016/j.neuron.2019.03.01310.1016/j.neuron.2019.03.013 ↗
46. 10.1016/j.neuropharm.2015.11.02710.1016/j.neuropharm.2015.11.027 ↗